 BARCELONA, Spain, June 19, 2019 PRNewswire -- Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, one of the worlds three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEALTM fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEALTM, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicons airless spray device technology. 